Article thumbnail

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

By Marc E. Rothenberg, Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter Fahey Weller, Hans-Uwe Simon, Lawrence B. Schwartz, Lanny J. Rosenwasser, Johannes Ring, Elaine F. Griffin, Ann E. Haig, Paul I.H. Frewer, Jacqueline M. Parkin and Gerald J. Gleich


The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity

Publisher: 'Massachusetts Medical Society'
Year: 2016
DOI identifier: 10.1056/nejmoa070812.
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.